venturevaluation.com

Early-stage biotech and life sciences companies are rarely valued on revenue. When a company is preclinical or in early clinical trials, standard multiples such as EV/Revenue or EV/EBITDA have nothing to attach to. Instead, independent valuation work shifts to the value of the pipeline itself: what has been discovered, how far it has progressed, what it could become, and how much risk stands between today and that outcome. The core methods are risk-adjusted net present value (rNPV), milestone-based discounted cash flow, and cost-to-recreate, supported by evidence on stage, patents, market size, and comparable licensing deals.

Why Standard Valuation Multiples Break Down

Revenue multiples assume a company has revenue that is stable enough to extrapolate. Public comparables assume there is a pool of similar listed companies whose trading prices reveal what the market will pay. For a preclinical biotech, both assumptions fail:

• No revenue, or only grant and collaboration income. A company two years from a Phase 1 readout may have no product sales at all.
• Few true comparables. Two biotechs can share a therapeutic area and still differ enormously in mechanism, patent life, trial design, and partner interest.
• Value is concentrated in future, contingent events. Most of the value sits in milestones that may never be reached.
• Binary risk. A single failed trial can eliminate most of the value, which a smooth discount rate does not capture well.

This is why valuation in these sectors is built from the asset up, not from the income statement down.

The Main Valuation Approaches

Risk-Adjusted Net Present Value (rNPV)

rNPV is the workhorse method for development-stage assets. You forecast the cash flows a product would generate if approved, discount them to present value, then multiply by the probability of technical and regulatory success (PTRS) at each stage.

A simplified structure:

The critical judgment is the PTRS. Published stage benchmarks exist (for example, historical transition rates from Phase 1 to approval), but they should be adjusted for the specific asset: a novel modality in a hard-to-treat indication carries more risk than a reformulation of an approved drug.

Milestone-Based Discounted Cash Flow

When a company is negotiating a license or partnership, valuation often focuses on the deal structure rather than a single enterprise value. Milestone-based DCF models each payment separately:

• Upfront payment — received at signing, low risk, discounted lightly.
• Development milestones — tied to trial starts, data readouts, or filings; each carries its own probability.
• Regulatory milestones — tied to approval; higher probability than early development but still contingent.
• Sales milestones and royalties — depend on commercial performance; modeled with a revenue forecast.

This approach is useful because it mirrors how licensing deals are actually structured and lets both sides see which milestones drive most of the value.

Cost-to-Recreate

Cost-to-recreate estimates what it would cost a third party to rebuild the asset or platform from scratch: repeating the research, repeating the trials, refiling patents, and re-establishing know-how. It is most defensible when:

• The asset is very early and future cash flows are too speculative to model.
• The value lies in a platform, dataset, or tool rather than a single drug.
• The purpose is internal planning or a sanity check on other methods.

Its weakness is that cost does not equal value. A company can spend heavily and still hold an asset with little commercial prospect.

When to Use Which

Evidence an Independent Valuation Relies On

A credible assessment is only as good as its inputs. Expect the following to be examined:

• Pipeline stage and data quality. Preclinical, Phase 1, Phase 2, or later; whether the data are blinded, randomized, or from a small open-label study.
• Patent and licensing position. Composition-of-matter versus method patents, remaining patent life, freedom to operate, and whether rights are licensed in from a university or another company.
• Addressable market. Epidemiology, diagnosed and treated populations, standard of care, pricing benchmarks, and competition already approved or in development.
• Partnering and deal comparables. Upfronts, milestones, and royalties from similar-stage deals in the same therapeutic area. Databases of licensing transactions are commonly used to anchor these assumptions.
• Development and regulatory risk. Mechanism novelty, endpoint validation, regulatory pathway, and manufacturing complexity.
• Team and financing position. Cash runway, ability to fund the next stage, and dependence on a single partner.

Independent Assessment vs. Formal Fair-Market Valuation

These are related but not identical:

• Independent assessment supports internal planning, fundraising discussions, or licensing strategy. It is an analytical view of what an asset could be worth under stated assumptions. It is often used to prepare for negotiations or to test whether a proposed deal makes sense.
• Formal fair-market valuation is typically prepared for financial reporting, tax, litigation, or transaction purposes. It follows applicable standards, documents methodology and assumptions in detail, and may need to withstand scrutiny from auditors, regulators, or a court.

If you need a number for a board deck or a term sheet discussion, an independent assessment is usually sufficient. If you need a number for an audit, a tax filing, or a dispute, you need a formal valuation with the corresponding documentation.

Common Pitfalls

• Over-reliance on peak-sales forecasts. A single optimistic peak-sales figure can dominate the entire rNPV. Test multiple scenarios and show sensitivity.
• Ignoring dilution and financing risk. Future rounds dilute existing holders, and a company that cannot fund the next trial may have to license on unfavorable terms.
• Treating PTRS as fixed. Success probabilities vary by indication, modality, endpoint, and company experience.
• Skipping regulatory and reimbursement risk. Approval is not the same as reimbursement; payers may restrict access or demand discounts.
• Using the wrong comparables. A deal for a Phase 3 asset is not a benchmark for a preclinical program.
• Double-counting or omitting costs. Remaining development costs must be deducted; already-spent costs are sunk and generally not added back.
• Forgetting patent cliffs and competition. Exclusivity ends, and a competitor may launch first.

A Practical Starting Checklist

If you are preparing for a valuation of an early-stage life sciences company, assemble:

1. Pipeline table: asset, indication, stage, next milestone, expected timing.
2. Patent and license summary: type, expiry, territory, royalty obligations.
3. Market model: patient population, penetration, price, competition.
4. Comparable deals: stage, therapeutic area, upfront, milestones, royalties.
5. Cost forecast: remaining R&D, trial, manufacturing, and regulatory costs.
6. Risk assumptions: PTRS by stage, discount rate, and rationale.
7. Scenario analysis: base, upside, and downside cases with the drivers that change.

Early-stage biotech valuation is less about finding one correct number and more about making assumptions explicit, testing them, and understanding which ones move the result. That discipline is what makes an independent assessment useful in planning, fundraising, and licensing discussions alike.

Early-stage startup valuation is not a single calculation. It is a negotiation anchored by a few defensible methods. For pre-revenue companies, investors and founders typically use the Berkus method or a scorecard, then cross-check the result with the venture capital (VC) method and market comparables. For companies with early revenue, the VC method and revenue multiples become more reliable. Discounted cash flow (DCF) is usually reserved for later stages where cash flows can be forecast with some confidence. The right method depends on stage, sector, and the purpose of the valuation (fundraising, option grants, or internal planning).

Pre-money vs. post-money: the number that actually matters in a term sheet

Founders often quote a valuation without specifying which one. This causes real confusion in negotiations.

• Pre-money valuation is the value of the company before new money comes in.
• Post-money valuation = pre-money + the amount invested.

If an investor puts in $2M at a $8M pre-money valuation, the post-money is $10M, and the investor owns 20% ($2M / $10M).

Why this matters: term sheets and dilution math are usually built on pre-money. A "$10M valuation" can mean very different ownership outcomes depending on which figure is being referenced. Always confirm which one is being discussed before comparing offers.

Matching the method to the stage

For biotech and life sciences specifically, valuation often leans on licensing and deal comparables rather than revenue multiples, because clinical-stage companies may have no product revenue at all. Databases of licensing deals and partnering transactions are commonly used as sanity checks in this sector.

The VC method, step by step

The VC method works backward from a future exit to today's value. It is the most common framework for early-stage fundraising.

1. Forecast an exit value. Estimate what the company could be worth at exit (typically 5–7 years out). This can be based on comparable acquisitions, projected revenue at exit multiplied by a sector multiple, or a target IPO value.
2. Apply the expected return multiple. A VC targeting a 10x return on a high-risk early-stage deal will divide the exit value by 10. This reflects the risk and the fund's return requirements.
3. Discount back to today. The result is the post-money valuation the VC needs to hit their target return. Subtract the investment amount to get the pre-money.

Example: A company forecasts a $100M exit in 5 years. The investor requires a 10x return. Post-money target = $100M / 10 = $10M. If the investor puts in $2M, the pre-money is $8M.

The return multiple is the key judgment call. It reflects stage, sector, and the fund's own strategy. Earlier and riskier deals demand higher multiples.

Adjusting for dilution, option pools, and future rounds

A target return multiple is not the same as the founder's outcome. Two adjustments are often overlooked:

• Dilution from future rounds. If the company will raise additional rounds before exit, the current investor's ownership will be diluted. The VC method should account for this by either using a higher required multiple or explicitly modeling future dilution.
• Option pool. Investors often require an option pool to be created or expanded before the investment (pre-money). This dilutes existing shareholders, not the new investor. The size of the pool (often 10–20% for early-stage) directly affects the effective pre-money valuation.

Ignoring either of these can make a headline valuation look better than the actual economic outcome for founders.

Sanity checks: comparables and deal data

No single method should stand alone. Cross-check the VC method result against:

• Comparable company valuations — what similar-stage companies in the same sector have raised at recently.
• Comparable transactions — acquisition prices for similar companies.
• Licensing and partnering deals — especially relevant in biotech, pharma, and life sciences, where deal terms (upfront payments, milestones, royalties) provide real market signals.

In sectors like biotech and life sciences, where revenue is often years away, these deal-based benchmarks are frequently more informative than revenue multiples. Venture Valuation, for example, specializes in independent assessments in biotech/life sciences and operates Biotechgate, a business development database covering global licensing deals and opportunities.

Common pitfalls

• Double-counting risk. If you apply a high discount rate and a high return multiple, you may be penalizing the same risk twice. Pick one consistent framework.
• Ignoring dilution. A valuation that looks strong today can shrink significantly after two more rounds.
• Over-relying on one method. The VC method, scorecard, and comparables each capture different things. Use at least two and explain the gap.
• Confusing pre-money and post-money. This is the most common source of disagreement in term sheet discussions.
• Using DCF too early. For pre-revenue companies, DCF requires assumptions that are essentially guesses. It is better suited to later stages.

What to do next

If you are preparing for a raise:

1. Identify your stage and pick two methods (e.g., scorecard + VC method for pre-revenue).
2. Build the VC method with explicit assumptions: exit value, return multiple, dilution, and option pool.
3. Gather 5–10 comparables from your sector, including licensing deals if you are in biotech or life sciences.
4. Present a range, not a single number, and be ready to explain the assumptions behind it.

The goal is not to find the "true" value. It is to build a defensible, transparent case that both sides can negotiate from.

Technology valuation estimates what an intangible asset—software, a patent, a drug candidate, a process—is worth today. When there is no revenue, you cannot rely on a simple multiple of sales or profits. Instead, you value the technology by estimating the future cash flows it could generate, adjusting heavily for the risk that it never gets there, or by using the cost to recreate it or prices paid for similar assets. The right method depends on the technology's stage, the availability of comparable deals, and the purpose of the valuation (fundraising, licensing, financial reporting, or negotiation).

What Makes Technology Valuation Different

Standard company valuation looks at revenue, earnings, and cash flow. Technology valuation looks at the asset behind those numbers—or behind the promise of them.

Key differences:

• The asset is intangible. Value sits in IP, know-how, data, code, or a patent portfolio, not in physical plant.
• Stage drives method. A concept, a prototype, a validated prototype, and a regulatory-approved product are valued very differently.
• Risk is the dominant variable. Technical, regulatory, and commercial uncertainty must be priced in explicitly, usually through probability-weighted cash flows or high discount rates.
• Comparables are scarce and imperfect. Few technologies are truly alike, so deal data must be adjusted for stage, indication, market size, and geography.
• Value is context-dependent. The same technology can be worth more to a strategic buyer with manufacturing and distribution than to a financial investor.

The Main Valuation Methods

Cost Approach

Sum what it would cost to recreate the technology today: R&D spent, developer time, IP filing and prosecution, testing, and opportunity cost. It sets a floor and is useful for early-stage assets, but it says nothing about whether anyone will pay for the result.

Market Approach

Use prices from comparable licensing deals, acquisitions, or royalty rates. For biotech and life sciences, databases of global licensing deals and opportunities are a practical starting point because they show real terms rather than theoretical models. Adjust for differences in stage, therapeutic area, market size, exclusivity, and territory.

Income Approach (DCF)

Project future cash flows—revenue, licensing income, cost savings—then discount them to present value. For pre-revenue technology, this means modeling scenarios: success, delay, partial success, failure. Probability-weight the scenarios or apply a risk-adjusted discount rate.

Option-Based Approach

Treats the technology as a series of options: invest to the next milestone, or stop. This fits drug development, deep tech, and any asset with clear go/no-go stages, because it values the flexibility to abandon a failing project.

Adjusting for Risk When There Is No Revenue

With no revenue, risk adjustment is the whole game. Common levers:

• Probability of technical success — likelihood the technology works as intended.
• Probability of regulatory success — for regulated products, approval risk.
• Probability of commercial success — will the market adopt it at the assumed price?
• Discount rate — early-stage assets often use rates far above those for established companies, reflecting the chance of total loss.
• Time to cash flow — the longer the wait, the more the discounting hurts.
• Milestone payments — licensing structures often shift risk between parties, changing value to each side.

A practical habit: build a base case, a downside case, and an upside case, then show how value changes when each key assumption moves. This sensitivity analysis is often more useful to investors and negotiators than a single number.

Using Comparables and Licensing Data

When direct cash flow is unavailable, deal data fills the gap. Look for:

• Royalty rates by industry and stage
• Upfront, milestone, and total deal values
• Equity stakes taken in lieu of cash
• Territory and exclusivity terms

Adjust each comparable for stage, indication or application, market size, patent life, and competitive position. A phase 1 asset and a marketed product are not comparable without heavy adjustment.

Documenting Assumptions and Sensitivities

A valuation is only as credible as its assumptions. Record:

1. The valuation date and purpose
2. The method chosen and why
3. Every key assumption, with its source
4. The scenarios modeled and their probabilities
5. Sensitivity of value to the most uncertain inputs
6. Limitations and what would change the conclusion

This documentation lets the valuation support investment decisions, licensing negotiations, or financial reporting, and lets a reviewer test the logic rather than just the number.

A Worked Example

Suppose a startup holds a patented diagnostic technology. It has no revenue, a working prototype, and one pending regulatory pathway.

• Cost approach: total R&D and IP spend to date is $2M. This sets a floor.
• Market approach: comparable diagnostic licensing deals suggest a 4–7% royalty on net sales. Applying that to a projected $50M peak market gives a range of royalty income.
• Income approach: model launch in year 4, peak sales $50M, 20% probability of regulatory approval, and a 30% discount rate. Probability-weighted, risk-adjusted cash flows produce a present value well below the undiscounted total.
• Option approach: value the option to fund the next trial and abandon if results disappoint.

The final range—not a single point—reflects the uncertainty. Presenting the range, with the assumptions behind each end, is what makes the valuation usable.

Choosing a Method

• Earliest stage, no data: start with cost, sanity-check with market comparables.
• Clear milestones and go/no-go decisions: option-based or scenario-weighted DCF.
• Comparable deals available: market approach, adjusted for differences.
• Forecastable cash flows: income approach with explicit risk adjustment.
• Negotiation or fundraising: combine methods and present a range with sensitivities.

Most defensible valuations use more than one method and reconcile the results.

Early-stage biotech and life sciences companies are usually valued by combining several methods rather than relying on a single formula. Because most have little or no revenue, no profits, and few truly comparable public companies, independent valuation firms typically blend a risk-adjusted income approach (discounted cash flow on projected pipeline revenues), market-based benchmarks from licensing and M&A deals, and a cost-based floor that reflects what has already been invested. The result is a range of values, not a precise number, and the assumptions behind it matter as much as the output.

Why Standard Valuation Multiples Break Down

For a mature business, valuation often starts with revenue or EBITDA multiples. For a pre-revenue biotech, that logic fails:

• There is no revenue to multiply.
• Earnings are negative by design, since R&D spending is the point.
• Comparable companies differ wildly in pipeline stage, indication, and cash position.
• Value sits in future, uncertain events (trial readouts, approvals, licensing deals), not in current operations.

So valuation shifts from "what is it earning?" to "what could it become, how likely is that, and how long until it happens?"

The Three Core Approaches

1. Risk-Adjusted Income Approach (rNPV)

The most common method for drug and device pipelines is risk-adjusted net present value (rNPV). You project future cash flows for each asset, multiply them by the probability of technical and regulatory success at each stage, then discount them back to today.

A simplified structure for one asset:

Each asset gets its own rNPV, and the company value is roughly the sum of the pipeline, plus cash, minus debt and ongoing overhead. The probabilities and discount rate are where most disagreement lives, which is why independent assessments document them explicitly.

2. Market Approach (Comparables and Deal Benchmarks)

Here you look at what similar assets or companies actually transacted for:

• Licensing deals: upfront payments, milestones, and royalties for assets at a comparable stage.
• M&A transactions: acquisition prices for companies with similar pipelines or platforms.
• Public comparables: market caps of listed peers, adjusted for stage and cash.

The challenge is comparability. A Phase III oncology asset is not the same as a Phase I rare-disease asset, even if both are "biotech." Analysts adjust for stage, indication size, competition, and geography. Databases of global licensing deals are often used to ground these benchmarks in real transactions rather than guesswork.

3. Cost Approach (Invested Capital Floor)

The cost approach asks: what would it take to recreate this asset or company from scratch? It sums historical R&D spend, IP costs, and team investment. This rarely sets the value on its own, but it provides a sanity floor, especially for very early platforms where future cash flows are too speculative to model credibly.

In practice, early-stage valuations weight the rNPV and market approaches most heavily, using the cost approach as a cross-check.

How Stage, Risk, and Licensing Potential Move the Number

Value is not linear in progress. A few drivers dominate:

• Pipeline stage: Each phase transition (preclinical → Phase I → II → III → approval) raises the probability of success and typically the value, often in steps rather than smoothly.
• Indication and market size: A large unmet need with pricing power supports higher peak sales assumptions.
• Competitive and regulatory risk: Crowded fields or tough endpoints lower success probabilities.
• Patent life and exclusivity: Shorter remaining protection compresses the revenue window.
• Licensing and partnering potential: A credible path to a partnership with upfront and milestone payments can raise value, because it de-risks and validates the asset.
• Platform vs. single asset: A platform that can generate multiple programs may justify a premium, but only if the repeatability is demonstrated.

Company Valuation vs. Technology or Product Valuation

These are related but not identical, and confusing them causes real problems:

• Technology/product valuation focuses on a specific asset, patent, or platform: its technical merit, freedom to operate, and standalone rNPV.
• Company valuation includes the technology but also cash, debt, team, overhead, other pipeline assets, and shareholder structure.

A single promising asset can be worth a lot in isolation, while the company holding it may be worth less if it carries heavy debt or burns cash quickly. When you request a valuation, be clear about which question you are asking.

What to Prepare Before Requesting an Independent Valuation

Good inputs produce defensible outputs. Before engaging a valuation firm, assemble:

1. Pipeline overview: each asset, indication, mechanism, and current stage.
2. Development plan and timeline: expected trial phases, costs, and milestones.
3. Market data: target patient population, pricing assumptions, competition.
4. IP position: patents, exclusivity, freedom to operate, remaining life.
5. Financials: historical spend, cash position, debt, burn rate.
6. Deal precedents: any licensing or partnership terms already discussed or signed.
7. Corporate structure: shares, options, convertible instruments.

The clearer these are, the fewer arbitrary assumptions the valuer has to make.

Common Limitations and Assumptions to Watch

• It is a range, not a point. Early-stage valuation is inherently uncertain; treat any single number with caution.
• Probabilities are estimates. Small changes in success rates or discount rates can swing value substantially.
• Comparables are imperfect. No two biotech assets are truly identical.
• Purpose matters. A valuation for fundraising, tax, litigation, or internal planning may use different standards and assumptions.
• Independence has value. An assessment from a party without a stake in the outcome is more defensible to investors, boards, and counterparties.

Practical Takeaway

If you are preparing an early-stage biotech or life sciences valuation, start with an rNPV for each asset, ground your assumptions in real licensing and M&A benchmarks, and use invested capital as a floor. Document every probability and discount rate you choose, because that is where scrutiny will focus. And decide up front whether you need a technology valuation, a company valuation, or both, since the answer changes what you should prepare and what the final number actually means.

Life sciences valuation estimates what a biotech, pharma, or medtech company or a specific asset (drug candidate, device, patent) is worth today. It differs from general startup valuation because value usually sits in a pipeline of products that may be years from revenue, each with its own probability of technical and regulatory success. The core approach is risk-adjusted: project future cash flows, then discount them for time and for the chance the asset never reaches market. Use rNPV (risk-adjusted net present value) for pipeline assets, comparable transactions for market benchmarks, and cost-to-duplicate for early or platform-stage work. Commission an independent valuation when the number must withstand scrutiny from investors, licensors, auditors, or a board.

Company valuation vs. asset valuation

These are different questions and often need different methods.

A company is rarely one number. For a clinical-stage biotech, the defensible figure is usually the sum of its programs' rNPVs, adjusted for shared costs, cash on hand, and any debt. Valuing the company as a single revenue multiple only works once there is meaningful, predictable revenue.

The core method: risk-adjusted NPV (rNPV)

rNPV is the standard for pre-revenue and clinical-stage assets. The logic:

1. Project the cash flows for the asset if it succeeds — development costs remaining, launch timing, revenue ramp, cost of goods, marketing, and eventual patent expiry.
2. Assign a probability of success (PoS) at each stage. This is the risk adjustment. A Phase 1 oncology asset and a Phase 3 medtech device carry very different probabilities.
3. Multiply the success-case cash flows by the cumulative probability of reaching each milestone.
4. Discount the result to present value using a rate that reflects the asset's risk and the cost of capital.

The output is a single present value that already embeds the chance of failure. This is why rNPV is preferred over plain DCF for pipelines: a plain DCF on a pre-revenue asset either ignores failure or hides it in the discount rate, which is harder to defend.

Where the probability of success comes from

PoS is the most contested input. Sources include:

• Published clinical development success rates by phase and therapeutic area (industry benchmark studies).
• The company's own data — mechanism, endpoint, trial design, competitive position.
• Comparable programs that succeeded or failed at the same stage.
• Regulatory pathway — accelerated approval, breakthrough designation, or standard review changes the timeline and risk.

Do not use a single blended PoS for a whole pipeline. Each asset has its own risk profile, and lumping them together is a common source of error.

Comparable transactions and licensing deals

For pre-revenue assets, the market's own pricing is powerful evidence. Licensing deals, acquisitions, and partnership terms reveal what buyers actually paid for similar assets at similar stages.

Use comparables to:

• Sanity-check an rNPV. If your rNPV is far above every comparable deal, explain why.
• Derive milestone and royalty structures. Upfront payments, development milestones, sales milestones, and royalty rates are observable in disclosed deals.
• Benchmark stage-specific values. A Phase 2 asset in a given therapeutic area has a rough range based on prior deals.

Venture Valuation runs Biotechgate, a business development database covering global licensing deals and opportunities, which is the kind of source used to build these comparables. The quality of a comparable analysis depends on matching stage, indication, modality, and deal structure — not just headline value.

Milestone and royalty analysis

When an asset is licensed rather than sold outright, value is split across:

• Upfront payment — received at signing, low risk.
• Development milestones — tied to clinical or regulatory events, probability-weighted.
• Sales milestones — tied to revenue thresholds, probability-weighted and time-discounted.
• Royalties — a percentage of future sales, discounted for time and risk.

Each component is valued separately and then summed. A large headline "biobucks" number is not value; the risk-adjusted present value of the components is.

Cost-to-duplicate

For very early assets, platforms, or technologies with no clear lead product, cost-to-duplicate asks: what would it cost to rebuild this from scratch today?

Inputs include:

• Research and development spent to date (adjusted for what is still useful).
• Cost to repeat the experiments, trials, or engineering.
• Time and talent required.
• IP position — patents, exclusivity, freedom to operate.

This method sets a floor rather than a market value. It is useful when there is no revenue, no comparable deal, and no reliable PoS — for example, a discovery-stage platform. It is weak when the asset's value comes from being first or from data that cannot simply be recreated.

Adjusting for stage, patent life, and regulatory risk

The same science can be worth very different amounts depending on context.

• Clinical stage — value generally rises sharply as an asset passes each phase, because both remaining cost and risk fall.
• Patent life and exclusivity — revenue only accrues while protection lasts. A short remaining patent life caps value regardless of clinical merit.
• Regulatory risk — different agencies, pathways, and indications carry different approval probabilities and timelines.
• Competitive landscape — a crowded indication with entrenched standards of care lowers the achievable price and market share.
• Reimbursement — for medtech and diagnostics, payer coverage is a real risk that belongs in the cash-flow assumptions.

Evidence to gather before a valuation

A valuation is only as good as its inputs. Collect:

• Pipeline data — stage, indication, mechanism, trial design, endpoints, readout timing.
• Deal comparables — licensing and M&A transactions in the same space, with structure.
• IP — patents, expiry, exclusivity, freedom to operate.
• Financial projections — remaining development cost, launch timing, pricing, market size, cost of goods.
• Probability evidence — benchmark success rates and program-specific risk factors.
• Company financials — cash, burn, debt, and shared overhead.

Common pitfalls

• Double-counting risk. Applying a low PoS and a very high discount rate to the same cash flows penalizes the asset twice.
• Revenue multiples on pre-revenue assets. A multiple needs revenue. Using one on a pipeline asset produces a number with no basis.
• Ignoring patent life. A successful drug with two years of exclusivity left is not worth the same as one with twelve.
• Using one blended PoS. Different assets, different risks.
• Treating headline deal value as value. Upfront, milestones, and royalties must be separated and risk-adjusted.
• Forgetting shared costs. Company-level value must account for overhead, not just asset rNPVs.

When to commission an independent valuation

An independent valuation is worth the cost when the number must be defensible to an outside party:

• Licensing or partnering — to negotiate upfront, milestone, and royalty terms.
• Fundraising — to support a raise with a documented, method-based figure.
• Financial reporting — impairment testing, purchase price allocation, or fair-value measurement.
• Board and investor decisions — where a single internal number would be challenged.

Venture Valuation specializes in independent assessments and valuations of companies and products in biotech and life sciences, which is the profile of provider to engage when independence and method transparency matter.

Practical starting point

If you need a number now:

1. List every asset separately.
2. Build an rNPV for each, with an explicit PoS and discount rate.
3. Support the PoS and deal terms with comparables.
4. Sum the asset values, then adjust for cash, debt, and overhead.
5. Stress-test the result against comparable transactions and cost-to-duplicate.

If the asset is too early for rNPV, use cost-to-duplicate as a floor and comparables as a range, and state clearly which method produced which number.